Table 2.
Intraoperative opioid, anaesthetic and transfusion requirements of 56 patients.
| Placebo | Dex | P-value | |
|---|---|---|---|
| n = 30 (53.6%) | n = 26 (46.4%) | ||
| Midazolam premedication | |||
| n (%) | 8 (26.7%) | 5 (19.2%) | 0.511a |
| Propofol bolus | |||
| n (%) | 29 (96.7%) | 26 (100%) | 0.732a |
| Cum.; mg; Median [IQR] | 180 [150–200] | 185 [140–200] | 0.706b |
| TIVA with propofol | |||
| n (%) | 6 (20%) | 9 (34.6%) | 0.454a |
| mg/kg/h; Median [IQR] | 3.77 [3.33–5.91] | 3.65 [3.0–4.96] | 0.680b |
| Sevoflurane | |||
| n (%) | 1.45 [1.25–1.75] | 19 (73.1%) | 0.426a |
| et vol%; Median [IQR] | 21 (70.0%) | 1.37 [1.15–1.55] | 0.126b |
| Desflurane | |||
| n (%) | 10 (33.3%) | 7 (26.9%) | 0.386a |
| et Vol%; Median [IQR] | 4.44 [4.10–4.81] | 3.86 [3.45–4.55] | 0.079b |
| Fentanyl | |||
| n (%) | 24 (80%) | 20 (76.9%) | 0.642a |
| Cum.; mg; Median [IQR] | 0.5 [0.36–0.93] | 0.44 [0.40–0.75] | 0.661b |
| Sufentanile | |||
| n (%) | 6 (20.0%) | 7 (26.9%) | 0.369a |
| Cum.; µg; Median [IQR] | 194 [102.53–298.73] | 201 [100–235] | 0.886b |
| Rocuronium | |||
| n (%) | 18 (60%) | 15 (57.7%) | 0.188a |
| Cum.; mg; Median [IQR] | 67.5 [50–100] | 90 [80–115] | 0.061b |
| Cisatracurium | |||
| n (%) | 13 (43.3%) | 11 (42.3%) | 0.372a |
| Cum.; mg; Median [IQR] | 17 [13–25.50] | 15 [15–20] | 0.600b |
| RBC Transfusion | |||
| n (%) | 4 (13.3%) | 3 (11.5%) | 0.421a |
| Cum.; ml; Median [IQR] | 320 [308.5–744.75] | 620 [310–620] | 0.372b |
Statistical analysis was conducted between patients receiving standard general anaesthesia (Placebo) and dexmedetomidine in addition to general anaesthesia (Dex).
Cum. cumulative dose in all patients, Dex Dexmedetomidine, IQR Interquartile range. n (%) number of patients who received the drug or transfusion at least once (expressed as percentage), RBC red blood cell, TIVA totally intravenous anaesthesia.
aCategorical variables analysed by Chi2 test.
bContinuous variables analysed by Mann–Whitney U test.